Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer
NCT05411380Phase 2Unknown
- Start
- Oct 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in breast cancer. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05411380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05411380.